住院药物使用障碍合并感染并发症的连续性照护:整合诊所对照常规治疗预防感染相关再住院的CHOICE-STAR随机对照试验方案
CHOICE-STAR是一项在美国五家医院开展的混合1型随机实效-实施试验,纳入约304例因注射阿片类或兴奋剂相关感染住院的患者,评估整合感染病与物质使用障碍门诊对6个月感染相关再住院的效果,并评估实施结局与成本效果。
要点
- 整合诊所将物质使用障碍治疗与感染病诊疗整合于同一次预约、同一地点。
- 主要结局为6个月感染相关再住院,另随访6个月评估干预结束后结局。
- 研究采用EPIS框架指导实施,并评估实施结局与成本效果。
核心结论
- 该试验旨在填补注射吸毒者严重注射相关细菌和真菌感染出院后照护的证据空白,若有效可减少再住院并提高治疗完成率。
研究设计与样本
- 混合1型随机实效-实施试验,由EPIS框架指导,在美国五家医院开展,计划纳入约304名参与者。
- 研究对象为因注射阿片类或兴奋剂相关感染住院的患者。
主要发现
- 原文未报告研究结果,仅报告研究方案。
- 原文指出注射吸毒者严重注射相关细菌和真菌感染再住院率超过50%在1年内。
关键数值与推荐
- 整合诊所提供低门槛物质使用障碍照护,包括阿片类使用障碍药物(MOUD)和减害服务,整合于单次预约和单一地点,至少每月预约一次、持续6个月。
- 整合诊所包括感染病与物质使用障碍提供者每周一次的照护协调会议。
- 主要结局为6个月感染相关再住院。
- 额外6个月随访评估干预完成后结局。
临床怎么用
- 若证实有效,整合照护模式可为医疗系统提供可复制的框架,用于管理注射吸毒者严重注射相关感染出院后的照护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People who inject drugs (PWID) experience high rates of serious injection-related bacterial and fungal infections (SIRI), including cellulitis, osteomyelitis, and endocarditis. These infections often require prolonged antibiotic treatment and result in frequent rehospitalizations, with over 50% of patients readmitted within 1 year. Few evidence-based interventions exist to optimize continuity of care for addiction, management, and prevention of SIRI following hospitalization. METHODS: CHOICE-STAR is a hybrid type 1 randomized effectiveness-implementation trial, guided by the Exploration, Preparation, Implementation, and Sustainment Framework (EPIS), conducted at five hospitals across the USA. The study aims to assess the effectiveness of the integrated infectious diseases (ID) and substance use disorder (SUD) outpatient clinic on 6-month infection-related rehospitalization among people hospitalized with an infection related to injecting opioids or stimulants. The study also includes implementation outcomes guided by Proctor's Implementation Outcomes taxonomy, as well as cost-effectiveness outcomes. The integrated clinic (IC) will offer facilitated linkage to a clinic providing medical care aimed at treating SUD and ID by completing treatment for the index infection, treating existing ID complications of SUD, and preventing subsequent infections by providing low barrier care for SUD including medication for OUD (MOUD) and harm reduction integrated into a single appointment and co-located at a single site for a minimum of monthly appointments over a 6 month time period. An additional 6 months' follow-up will be included to assess outcomes following the completion of the intervention. The IC includes a weekly care coordination meeting between the ID and SUD providers. The study will enroll approximately 304 participants. DISCUSSION: This trial addresses a critical gap in post-hospitalization care for PWID with SIRI. If effective, the integrated care model could significantly reduce rehospitalizations, improve treatment completion, and provide a replicable framework for healthcare systems. The study's implementation science components will inform the scalability and sustainability of this intervention. Results will inform evidence-based policy and practice recommendations for managing this high-risk population, potentially leading to improved patient health outcomes. TRIAL REGISTRATION: ClinicalTrials.gov NCT06513156 . Registered on August 09, 2024.
引用
- Rosenthal ES, Lavoie MC, Traver E, et al. Continuum of care in hospitalized patients with opioid or stimulant use disorder and infectious complications of drug use-substance use/infectious disease integrated clinic compared to treatment as usual to prevent infection-related readmission (CHOICE-STAR): a study protocol for an effectiveness-implementation randomized controlled trial. Trials. 2026. PMID: 41776656. doi:10.1186/s13063-026-09550-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。